Percutaneous Closure of Patent Foramen Ovale for Cryptogenic Stroke: The Issue is Finally Settled

Authors

  • Antonis S Manolis Third Department of Cardiology, Athens University School of Medicine, Athens, Greece

Keywords:

cryptogenic stroke, paradoxical embolism, patent foramen ovale, percutaneous closure

Abstract

Based on newer data from randomized controlled trials and meta-analyses, the previously controversial and highly debated issue of patent foramen ovale (PFO) closure in patients with cryptogenic stroke is finally settled in favor of closure over medical therapy for the secondary prevention of cryptogenic stroke attributable to paradoxical embolism. One PFO closure device finally received FDA approval in October 2016. Rhythmos 2017; 12(4):60-62.

Downloads

Published

2017-12-28

Issue

Section

Editorial